Wave Life Sciences Ltd. registered 300,000 ordinary shares on Form S-8, covering shares issuable upon exercise of options granted to a new employee under an Inducement Non-qualified Share Option Agreement dated May 27, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
This filing adds registered capacity specifically tied to that inducement option grant. It is an administrative step that facilitates the issuance of shares if and when the employee exercises the options.
Wave Life Sciences Ltd. reported Q3 2025 results. Revenue was $7.6 million, primarily from the GSK collaboration, against operating expenses of $64.0 million, resulting in a net loss of $53.9 million (basic and diluted loss per share $0.32). Other income contributed $2.5 million, mainly from interest.
Cash and cash equivalents totaled $196.2 million at September 30, 2025. Net cash used in operating activities for the first nine months was $153.7 million, partly offset by financing inflows including $42.6 million from the at-the-market equity program. Subsequent to quarter-end, the company received an additional $52.1 million in net ATM proceeds.
Deferred revenue was $58.2 million allocated to unsatisfied obligations, with $46.5 million current and $11.7 million long-term. The GSK collaboration recognized $7.6 million in Q3 revenue; a $10.0 million AATD milestone was acknowledged subsequent to quarter-end. Shareholders’ equity was $124.5 million. Ordinary shares outstanding were 167,181,784 as of November 7, 2025.
Wave Life Sciences Ltd. filed an 8-K announcing financial results for the quarter ended September 30, 2025. The accompanying press release was furnished as Exhibit 99.1 and incorporated by reference.
The company states the Item 2.02 information is being furnished and not deemed filed under the Exchange Act. Wave’s ordinary shares trade on The Nasdaq Global Market under the symbol WVE.
Wave Life Sciences filed an 8-K/A to correct a typographical error in Exhibit 99.1 of a prior 8-K and furnished the corrected press release. The company also hosted a Research Day webcast and issued a release summarizing key updates, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity. Certain information was furnished under Item 7.01 and incorporated by reference under Item 8.01.
Wave Life Sciences (WVE) filed an 8-K announcing a Research Day webcast held on October 29, 2025, and made the slide presentation available on its investor website. The company also furnished a press release summarizing highlights from the event, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity.
The materials are provided under Regulation FD as Item 7.01 information furnished, not filed, and thus are not subject to Section 18 liabilities. The press release (other than its second paragraph) is incorporated by reference into Item 8.01. Exhibit 99.1 contains the press release; the cover page interactive data file is included as Exhibit 104.
Wave Life Sciences Ltd. furnished an updated corporate presentation to the investment community. The presentation, dated September 24, 2025, provides updates and summaries of the company’s business and is available in the “For Investors & Media” section of its website and as Exhibit 99.1. The information is furnished under a regulation fair disclosure item and is not considered filed for liability purposes under the Exchange Act, unless specifically incorporated into another filing.
Wave Life Sciences reported that its drug candidate WVE-006 showed positive data in the ongoing Phase 1b/2a RestorAATion-2 study for alpha-1 antitrypsin deficiency (AATD). This is an early- to mid‑stage clinical trial, so positive results can be an important step toward later-stage development if they are confirmed over time.
The company also scheduled an investor conference call at 8:30 a.m. ET on September 3, 2025, to discuss the results and plans to share an investor slide presentation on its website. Most of the information in the related press release is being treated as supplemental disclosure rather than as part of its formal financial reporting.
Gregory L. Verdine, a director of Wave Life Sciences Ltd. (WVE), reported a sale of 10,000 ordinary shares on 08/22/2025 at a price of $10 per share, executed under a Rule 10b5-1 trading plan adopted March 13, 2025. After the reported disposition, Mr. Verdine beneficially owned 285,217 ordinary shares. The Form 4 was signed by Mr. Verdine on 08/26/2025 and indicates the transaction was effected pursuant to the specified 10b5-1 plan.
Paul B. Bolno, President and CEO and Director of Wave Life Sciences Ltd. (WVE), reported an insider sale. On 08/22/2025 he sold 217,351 ordinary shares under a Rule 10b5-1 trading plan adopted May 19, 2025. The weighted-average sale price was $10.098, with individual sale prices ranging from $10.00 to $10.27. After the reported transactions, the filing shows 121,000 ordinary shares beneficially owned by the reporting person. The Form 4 was signed on 08/26/2025 and notes the seller can provide detailed execution pricing by request.
Wave Life Sciences (WVE) submitted a Form 144 notice proposing the sale of 217,351 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $2,121,345.76, with an approximate sale date of 08/22/2025. The filing shows the shares were acquired as 26,495 Restricted Stock Units on 02/15/2021 and 190,856 Founders Shares on 03/31/2015. The filer reports nothing to report for securities sold in the past three months. The notice includes the standard signer representation that they are not aware of any undisclosed material adverse information.